ClinicalTrials.gg
CompletedNCT01522768Updated Nov 1, 2023Results posted

Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer

A Phase 2 interventional study of Afatinib and Paclitaxel in Esophageal Cancer and Gastric Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-01.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 80 studies testing paclitaxel in Esophageal Neoplasms — 11 open to participants now, 18 under way, none of them phase 3. Paclitaxel · Esophageal Neoplasms.

Enrollment
37th of 74
42 · median 40
Started
2012
the only one that year
Phase 2
48 of 80
6 open now
Registered
42nd of 80
by date
Lead sponsor
5 of 80
Memorial Sloan Kettering Cancer Center

Among the 80 studies testing paclitaxel in Esophageal Neoplasms, this one is the 37th largest by enrollment of the 74 interventional ones that give a count, is the only one that started in 2012, is one of 48 in phase 2, and was the 42nd registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

11 of the 80 studies testing paclitaxel in Esophageal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies testing paclitaxel in Esophageal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to find out what effects, good or bad, the combination of standard chemotherapy agent paclitaxel with the investigational (experimental) drug afatinib that targets HER2, has on HER2-positive esophagogastric cancer that started to get bigger despite previous treatment with trastuzumab. The doctors will also study the tumor to understand why it grew while on trastuzumab treatment and to see the effects afatinib and paclitaxel has on the tumor.

03

Conditions studied

  • Esophageal Cancer
  • Gastric Cancer

Keywords

  • ESOPHAGUS
  • STOMACH
  • Afatinib
  • paclitaxel
  • trastuzumab
  • 11-166
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed esophagogastric cancer.
  • overexpression and/or amplification as determined by immunohistochemistry (3+) or FISH (≥2.0)
  • Previously received trastuzumab as part of a regimen in the perioperative or setting with evidence of progression 9Zr-trastuzumab use as imaging agent for 89Zr-trastuzumab PET permitted..
  • May have previously received lapatinib as part of a regimen in the perioperative or metastatic setting with evidence of progression of disease. for lapatinib of 14 days.
  • Completion of previous chemotherapy regimen ≥2 weeks prior to the start of study treatment. Other chemotherapy regimens may have been administered between the time of progression on prior trastuzumab containing regimen and protocol therapy. No restriction on prior chemotherapy regimens for advanced stage disease.
  • At least one measurable metastatic lesion according to 1.1 criteria. Ascites, pleural effusions, and bone metastases are not considered measurable. Minimum indicator lesion size = 10 mm by helical CT or = 20 mm by conventional techniques. Pathological nodes must be = 15 mm by the short axis to be considered measurable.
  • Patients aged 18 years or older, as no dosing or adverse event data are currently available on the use of afatinib in patients \<18 years of age, children are excluded from this study.
  • of at least three (3) months.
  • performance status ≥60%
  • All patients with disease technically amenable to will be asked to undergo a biopsy. Patient must agree to allow 2 biopsies of any malignant lesion that can be accessed by endoscopy or with the aid or radiology (i.e. CT guided).
  • Patients who have previously provided samples at any time after trastuzumab resistance will be exempt from biopsy at the start of therapy.
  • Consent to preservation of frozen and fixed samples of tumor cores for evaluation
  • Able to swallow and retain oral medication.
  • Negative serum HCG pregnancy test for premenopausal women of reproductive capacity and for women less than 12 months after menopause.
  • Willingness to use while on study.
  • Asymptomatic, central nervous system metastases are permitted.

Exclusion criteria

Exclusion Criteria:

  • Patients receiving any concurrent anticancer therapy or agents with the intention of treating esophagogastric cancer. 89Zr-trastuzumab uses as imaging agent for 89Zr-trastuzumab PET permitted.
  • Prior disease progression on docetaxel or paclitaxel in setting.
  • Patients who are unwilling to consent to mandatory tumor . Patients with archival tissue permitted to enroll on study per MSK Principal Investigator discretion Women who are pregnant or breast feeding.
  • Concurrent radiotherapy is not permitted for disease progression on treatment on protocol (except in the context specified in section 9.0), but might be allowed for pre-existing non-target lesions with approval from the principal investigator of the trial.
  • Concurrent medical conditions which may increase the risk of toxicity, including ongoing or active infection, history of significant bleeding disorder unrelated to cancer (congenital bleeding disorders, acquired bleeding disorders within one year), -positive.
  • Subjects with acute are not eligible. Subjects with chronic hepatitis are eligible if their condition is stable and in the opinion of the investigator, if consulted, would not pose a risk to subject safety.
  • History or presence of cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure classification of 3, unstable angina or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to study entry.
  • Baseline (\< 1 month before treatment) cardiac left ventricular function with resting of less than 50% measured by echocardiogram.
  • Known pre-existing interstitial lung disease.
  • Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom e.g., Crohn's disease, malabsorption, or CTCAEGrade >2 diarrhea of any etiology.
  • Unwillingness to give written , unwillingness to participate, or inability to comply with the protocol for the duration of the study.
  • Active hepatitis B infection, active infection
  • Known HIV carrier
  • Known or suspected active drug or alcohol abuse. Restricted Therapies
  • Additional experimental anti-cancer treatment and/or standard chemo-, immunotherapy, hormone treatment (with the exception of megestrol acetate), or concurrent radiotherapy is not allowed concomitantly with the administration of study treatment (with the exception listed in section 9.0) 89Zr-trastuzumab use as imaging agent for 89Zr-trastuzumab PET permitted. Afatinib is a substrate of P-gp and its plasma concentrations can be affected by the use of P-gp inhibitors (data on file) and it is also likely that P-gp inducers could also influence afatinib plasma concentrations.
  • The use of potent P-gp inhibitors (including cyclosporine, erythromycin, ketoconazole, itraconazole, quinidine, Phenobarbital salt with quinidine, ritonavir, valspodar, verapamil) and potent P-gp inducers (including St John's wort, rifampicin) has to be avoided during treatment with afatinib. Any exemptions to this have to be discussed with the principal investigator.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Afatinib and Paclitaxel

    This is a multi-institution, open-label, non-randomized, Phase II evaluation of oral afatinib daily and intravenous paclitaxel (weekly, 3 weeks on, 1 week off) in patients with trastuzumab refractory HER2-positive metastatic or recurrent esophagogastric adenocarcinoma. An initial biopsy prior to the start of therapy is required for the correlative studies evaluating the biologic effects of afatinib. It will be obtained for all patients whose tumors are feasible to biopsy. At the site investigator's discretion, a second biopsy will also be obtained. At the discretion of the MSK Principal Investigator, select participants who show response on this study and then progress may be asked to have an optional third biopsy.

    Drug: Afatinib and Paclitaxel

Interventions

  • DrugAfatinib and Paclitaxel

    Drug pages: AfatinibStudies of AfatinibAfatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PaclitaxelStudies of PaclitaxelPaclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All patients receiving therapy on trial with afatinib and trastuzumab will continue on afatinib and trastuzumab until disease progression or intolerable toxicity. All additional patients will be enrolled on afatinib and paclitaxel. Patients will be treated with afatinib and paclitaxel combination. Patients will receive oral afatinib 40 mg daily plus paclitaxel 80 mg/m\^2 intravenously on day 1, 8, and 15 of a 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Efficacy

    of afatinib in patients with metastatic HER2-positive esophagogastric cancer as measured by overall clinical benefit defined as response rate (ORR) = stable disease (SD) complete response (CR) or partial response (PR) at 4 months by RECIST 1.1 criteria

    Time frame: 2 years

Secondary outcomes

  1. Number of Participants Evaluated for Toxicity

    The type, frequency, severity, timing, and relationship of each adverse event will be determined as per the NCI Common Toxicity Criteria, version 4.0.

    Time frame: 2 years

07

Results

Posted Nov 1, 2023

Participant flow

Participant flow — Overall Study
MilestoneAfatinib and Paclitaxel
Started42
Completed42
Not completed0

Outcome measures

PrimaryEfficacy

of afatinib in patients with metastatic HER2-positive esophagogastric cancer as measured by overall clinical benefit defined as response rate (ORR) = stable disease (SD) complete response (CR) or partial response (PR) at 4 months by RECIST 1.1 criteria

Time frame:
2 years
Reported as:
Count of participants · Participants
Efficacy
ParticipantsAfatinib and Paclitaxel
Partial Response4
Progression of Disease18
Stable Disease12
Not Evaluable8
SecondaryNumber of Participants Evaluated for Toxicity

The type, frequency, severity, timing, and relationship of each adverse event will be determined as per the NCI Common Toxicity Criteria, version 4.0.

Time frame:
2 years
Reported as:
Count of participants · Participants
Number of Participants Evaluated for Toxicity
ParticipantsAfatinib and Paclitaxel
Number of Participants Evaluated for Toxicity42

Adverse events

Collected over 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Afatinib and Paclitaxel2/42 (4.8%)22/42 (52.4%)41/42 (97.6%)
Most frequent serious events
Showing 10 of 79
Most frequent serious events
EventAfatinib and Paclitaxel
AnemiaBlood and lymphatic system disorders12/42
HyperglycemiaMetabolism and nutrition disorders12/42
DiarrheaGastrointestinal disorders9/42
Abdominal PainGastrointestinal disorders6/42
DehydrationMetabolism and nutrition disorders6/42
DyspneaRespiratory, thoracic and mediastinal disorders6/42
VomitingGastrointestinal disorders6/42
Lymphocyte count decreasedInvestigations5/42
HypoalbuminemiaMetabolism and nutrition disorders4/42
NauseaGastrointestinal disorders4/42
Most frequent other events
Showing 10 of 38
Most frequent other events
EventAfatinib and Paclitaxel
DiarrheaGastrointestinal disorders38/42
FatigueGeneral disorders21/42
Rash acneiformSkin and subcutaneous tissue disorders18/42
AnemiaBlood and lymphatic system disorders13/42
AnorexiaMetabolism and nutrition disorders12/42
Papulopustular rashSkin and subcutaneous tissue disorders8/42
Mucositis oralGastrointestinal disorders7/42
VomitingGastrointestinal disorders7/42
Dry skinSkin and subcutaneous tissue disorders6/42
HypokalemiaMetabolism and nutrition disorders6/42

Baseline characteristics

Age, Continuous
Age, Continuous(years)Afatinib and Paclitaxel
Median63 (37 to 80)
Sex: Female, Male
Sex: Female, Male(Participants)Afatinib and Paclitaxel
Female12
Male30
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Afatinib and Paclitaxel
Hispanic or Latino2
Not Hispanic or Latino40
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Afatinib and Paclitaxel
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American5
White34
More than one race0
Unknown or Not Reported2
Region of Enrollment
Region of Enrollment(Participants)Afatinib and Paclitaxel
United States42
08

Study locations

9 sites
  • University of Southern California
    Los Angeles, California 90033, United States
  • Massachusetts General Hospital Cancer Center
    Boston, Massachusetts 02114, United States
  • Memorial Sloan Kettering Basking Ridge
    Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth
    Middletown, New Jersey 07748, United States
  • Memorial Sloan Kettering Bergen
    Montvale, New Jersey 07645, United States
  • Memorial Sloan Kettering Commack
    Commack, New York 11725, United States
  • Memorial Sloan Kettering Westchester
    Harrison, New York 10604, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Memorial Sloan Kettering Rockville Centre
    Rockville Centre, New York, United States
09

References and documents

Publications

  • Sanchez-Vega F, Hechtman JF, Castel P, Ku GY, Tuvy Y, Won H, Fong CJ, Bouvier N, Nanjangud GJ, Soong J, Vakiani E, Schattner M, Kelsen DP, Lefkowitz RA, Brown K, Lacouture ME, Capanu M, Mattar M, Qeriqi B, Cecchi F, Tian Y, Hembrough T, Nagy RJ, Lanman RB, Larson SM, Pandit-Taskar N, Schoder H, Iacobuzio-Donahue CA, Ilson DH, Weber WA, Berger MF, de Stanchina E, Taylor BS, Lewis JS, Solit DB, Carrasquillo JA, Scaltriti M, Schultz N, Janjigian YY. EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. Cancer Discov. 2019 Feb;9(2):199-209. doi: 10.1158/2159-8290.CD-18-0598. Epub 2018 Nov 21. PubMed 30463996 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2012 to primary completion in Feb 2023, 131 months.

Results were first posted in Nov 2023, 8 months after primary completion.

Of 174 non-industry phase 2 interventional studies under Esophageal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 85. This study's 131 months is above that.

Counting every sponsor, half of 198 studies reached it within 52 months; a quarter within 33 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2012
First posted
Feb 1, 2012
StartActual
Mar 2012
Primary completionActual
Feb 20, 2023
CompletionActual
Feb 20, 2023
Results first posted
Nov 1, 2023
Last update
Nov 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01522768
Collaborators
Boehringer Ingelheim, University of Southern California, Dana-Farber Cancer Institute, United States Department of Defense
Responsible party
Sponsor
First posted
Feb 1, 2012
Start date
Mar 2012
Primary completion
Feb 20, 2023
Completion
Feb 20, 2023
Results posted
Nov 1, 2023
Last update
Nov 1, 2023

Study contacts

Yelena Janjigian, MD
principal investigator · Memorial Sloan Kettering Cancer Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Afatinib · Paclitaxel

Start the discussion